ISO 10993 Updates for 2026: Adapting Your Biocompatibility Strategy

## ISO 10993 Updates for 2026: Adapting Your Biocompatibility Strategy The anticipated updates to the ISO 10993 series of standards, expected around 2026, represent a significant evolution in how medical device biocompatibility is evaluated. This shift reinforces the global regulatory movement away from a prescriptive, checklist-based testing menu toward a more holistic and integrated risk management framework. For medical device manufacturers, this means the Biological Evaluation Plan (BEP) is no longer just a preliminary document but the central pillar of a comprehensive, science-driven safety assessment that must be maintained throughout the product lifecycle. This evolution places a greater emphasis on understanding a device's constituent materials at a chemical level. The goal is to proactively identify and assess potential toxicological risks before, and sometimes in place of, extensive biological testing. For manufacturers of devices with long-term tissue contact, adapting to these changes requires a strategic reassessment of supplier data, internal documentation, and the overall approach to demonstrating biological safety, in alignment with the principles outlined in FDA guidance documents. *** ### Key Points * **Risk Management is Central:** The updated approach moves definitively away from a "check-the-box" testing matrix. The entire biological evaluation process must now be driven by a comprehensive risk analysis documented in a living Biological Evaluation Plan (BEP). * **Chemical Characterization is Foundational:** ISO 10993-18 (Chemical Characterization) is increasingly used as a primary evaluation tool. Data from extractables and leachables (E&L) studies informs a toxicological risk assessment (per ISO 10993-17), which can justify the absence of certain in vivo tests. * **Proactive Supplier Management is Non-Negotiable:** Manufacturers must work closely with their supply chain to obtain detailed chemical composition data for all patient-contacting materials. If this data is unavailable or insufficient, planning for comprehensive E&L testing is essential. * **Legacy Devices Require Lifecycle Re-evaluation:** Marketed devices are not exempt. Any planned change to materials, suppliers, manufacturing processes, or sterilization methods triggers the need to re-evaluate biocompatibility against the current standards, documented within an updated Biological Evaluation Report (BER). * **The BEP is a Living Document:** The BEP and its corresponding BER are not "one-and-done" documents for a submission. They must be actively maintained and updated throughout the product lifecycle to reflect any changes that could impact biological safety. * **Early Regulatory Engagement is a Strategic Advantage:** For devices involving novel materials or complex risk profiles, using the FDA Q-Submission program to align on a biological evaluation strategy can prevent costly delays and redundant testing. *** ### Understanding the Core Shift: From Checklist to Risk Management Historically, biocompatibility evaluation often involved following the matrix in ISO 10993-1 to select a standard battery of tests based on device category and contact duration. While this approach provided a baseline, it could lead to unnecessary animal testing and sometimes failed to address device-specific risks. The modern framework, emphasized by both FDA guidance and the evolving ISO standards, reframes this process around risk management. The evaluation is no longer about simply completing tests but about demonstrating a deep understanding of the device and its potential biological interactions. The **Biological Evaluation Plan (BEP)** is the cornerstone of this process. It is a formal, written plan developed *before* any testing begins. A robust BEP should include: 1. **Device and Material Information:** A detailed description of the device, its intended use, the duration and nature of patient contact, and a complete list of all direct and indirect patient-contacting materials. 2. **Manufacturing Process Review:** An assessment of manufacturing processes (e.g., molding, machining, cleaning, sterilization) that could leave residues or alter material surfaces. 3. **Literature and Clinical History Review:** A summary of existing data on the materials and the device type, including any history of clinical use. 4. **Risk Analysis:** A systematic identification of potential biological risks based on the device's materials and intended use. This includes considering risks from leachable chemicals, particulates, degradation products, and surface properties. 5. **Evaluation and Testing Strategy:** The plan for addressing the identified risks. This section justifies the entire strategy, detailing which standard tests will be conducted, which will be omitted, and why. Crucially, it must outline the plan for chemical characterization and the subsequent toxicological risk assessment. *** ### The Rise of Chemical Characterization (ISO 10993-18) A key component of the risk-based approach is the increased reliance on chemical characterization to understand what substances could be released from a device during its use. This is typically achieved through an **extractables and leachables (E&L) study**. * **Extractables:** Chemicals that can be forced out of the device material under exaggerated laboratory conditions (e.g., aggressive solvents, high temperatures). This represents a "worst-case" scenario. * **Leachables:** Chemicals that migrate from the device under normal clinical use conditions. The data from these studies feeds directly into a **Toxicological Risk Assessment (TRA)**, as described in ISO 10993-17. Toxicologists use this chemical data to assess the potential health risk of each identified substance at its detected exposure level. A well-executed TRA can provide powerful evidence to justify that the device is safe, sometimes eliminating the need for long-term or systemic toxicity tests in animals. This aligns with the "3Rs" principle (Replace, Reduce, Refine animal testing) increasingly embraced by global regulators. The primary challenge for manufacturers is obtaining the necessary chemical information. Material suppliers may consider detailed formulations to be proprietary. Therefore, a proactive timeline for gathering this data or commissioning E&L testing is critical. An E&L study, including protocol development, analytical testing, and reporting, can take **6-9 months or more**, making it a long-lead item in a product development timeline. *** ### Scenarios: Applying the Risk-Based Approach #### Scenario 1: New Long-Term Implantable Device (e.g., Orthopedic Implant) A manufacturer is developing a new Class II orthopedic implant intended for permanent contact with bone and tissue. The device uses a polymer with a novel surface texturing. * **What Regulators Will Scrutinize:** * The thoroughness of the BEP and its justification for the evaluation strategy. * The quality and completeness of the chemical characterization data, likely requiring a rigorous E&L study. * The scientific soundness of the toxicological risk assessment that links the chemical data to patient safety. * The assessment of risks specific to the novel surface texturing, such as potential for particulate generation or altered tissue response. * **Critical Data to Provide:** * A comprehensive BEP that identifies all potential biological risks. * A full E&L study report identifying and quantifying chemical constituents. * A detailed TRA evaluating the safety of all identified leachables. * Biological testing to address endpoints that cannot be fully evaluated by chemical data alone, such as implantation (local tissue effects), hemocompatibility (if blood-contacting), and potentially sensitization or irritation. #### Scenario 2: Legacy Device with a Manufacturing Change (e.g., Catheter) A company has been marketing a vascular catheter for years. They plan to switch to a new, more efficient cleaning agent during manufacturing. * **What Regulators Will Scrutinize:** * The scientific justification that the change does not adversely affect the device's biological safety profile. A simple statement that the new agent is "commonly used" is insufficient. * A documented risk assessment comparing the potential residues from the old agent versus the new one. * Evidence that the new cleaning process does not alter the catheter's materials or introduce new contaminants. * **Critical Data to Provide:** * An updated Biological Evaluation Report (BER) or a memo-to-file that documents the change and the complete risk assessment. * Depending on the risk, this may require a targeted chemical characterization study to look for residues of the new agent and a TRA to assess their safety. * If the TRA is inconclusive or identifies a potential risk, targeted biological tests (e.g., cytotoxicity) may be required to confirm safety. Simply relying on the device's original biocompatibility data is not acceptable without a robust justification. *** ### Strategic Considerations and the Role of Q-Submission Proactively adapting to the evolving biocompatibility landscape is a strategic imperative. For devices with novel materials, unique manufacturing processes, or challenging risk profiles, engaging with the FDA early through the **Q-Submission program** is highly recommended. A Pre-Submission (Pre-Sub) meeting allows a sponsor to present their proposed biological evaluation strategy, including the BEP and plans for chemical and biological testing. This provides an opportunity to receive direct FDA feedback on the plan *before* initiating costly and time-consuming studies. This dialogue can de-risk the regulatory process, prevent misunderstandings about expectations, and ensure the planned evidence will be sufficient to support a future marketing submission. *** ### Finding and Comparing Biocompatibility Testing Services Providers Choosing the right contract research organization (CRO) or testing laboratory is critical for a successful biological evaluation. The provider must not only execute tests but also act as a strategic partner who understands the nuances of the risk-based approach. When selecting a provider, manufacturers should look for: * **Deep Regulatory and Standards Expertise:** The lab should have demonstrable experience with the latest versions of the ISO 10993 series and FDA's current thinking on biocompatibility. * **Integrated Services:** A provider that offers services across the entire evaluation spectrum—from planning (BEP development) to chemical characterization (E&L), toxicology (TRA), and biological testing—can ensure a more cohesive and efficient process. * **Strong Analytical Chemistry and Toxicology Teams:** The quality of the E&L study and the TRA are paramount. Inquire about the experience and qualifications of the chemists and toxicologists who will be assigned to the project. * **ISO 17025 Accreditation:** This accreditation demonstrates a laboratory's technical competence and ability to produce precise and accurate test data. When comparing options, request detailed proposals that outline the study designs, timelines, and the team's approach to problem-solving. A good partner will ask probing questions about the device to ensure the evaluation strategy is appropriate and defensible. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. *** ### Key FDA References * FDA Guidance: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process." * FDA Guidance on the Q-Submission Program. * Regulations under 21 CFR Part 820 (Quality System Regulation), which govern controls over materials, manufacturing processes, and suppliers. *** This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*